Therapeutic Time Window of Cannabidiol Treatment on Delayed Ischemic Damage via High-Mobility Group Box1-Inhibiting Mechanism
Authors:
- 1 January 2009
- journal article
- research article
- Published by Pharmaceutical Society of Japan in Biological and Pharmaceutical Bulletin
- Vol. 32 (9) , 1538-1544
Abstract
Cannabidiol decreases cerebral infarction and high-mobility group box1 (HMGB1) in plasma in ischemic early phase. However, plasma HMGB1 levels in ischemic delayed phase reach higher concentration with the progressing brain injury. In this study, we investigated the therapeutic time window of cannabidiol on functional deficits, glial HMGB1 and plasma HMGB1 levels in a 4 h mouse middle cerebral artery (MCA) occlusion model. Cannabidiol-treated mice were divided into 3 groups as follows: group (a) treated from day 1, group (b) treated from day 3, group (c) treated from day 5 after MCA occlusion. Moreover, minocycline, microglia inhibitor, and fluorocitrate, an inhibitor of astroglial metabolism, were used to compare with cannabidiol-treated group. Repeated treatment with cannabidiol from 1 and 3 d at the latest after cerebral ischemia improved functional deficits and survival rates. However, cannabidiol from 5 d could not improve the ischemic damage as well as fluorocitrate-treated group. Moreover, both group (a), group (b) and minocycline but not group (c) and fluorocitrate-treated group had a decrease in the number of Iba1 expressing HMGB1 positive cells and HMGB1 levels in plasma. Cannabidiol may provide therapeutic possibilities for the progressing brain injury via HMGB1-inhibiting mechanism.Keywords
This publication has 25 references indexed in Scilit:
- Cannabidiol prevents a post-ischemic injury progressively induced by cerebral ischemia via a high-mobility group box1-inhibiting mechanismNeuropharmacology, 2008
- Delayed treatment with cannabidiol has a cerebroprotective action via a cannabinoid receptor‐independent myeloperoxidase‐inhibiting mechanismJournal of Neurochemistry, 2007
- In silico patent searching reveals a new cannabinoid receptorTrends in Pharmacological Sciences, 2006
- Evidence for novel cannabinoid receptorsPharmacology & Therapeutics, 2005
- Cannabidiol prevents infarction via the non-CB1 cannabinoid receptor mechanismNeuroReport, 2004
- Cannabinoid pharmacology: implications for additional cannabinoid receptor subtypesChemistry and Physics of Lipids, 2002
- Neuroprotective Antioxidants from MarijuanaaAnnals of the New York Academy of Sciences, 2000
- Cannabidiol and (−)Δ 9 -tetrahydrocannabinol are neuroprotective antioxidantsProceedings of the National Academy of Sciences, 1998
- Controlled clinical trial of cannabidiol in Huntington's diseasePharmacology Biochemistry and Behavior, 1991
- Chronic Administration of Cannabidiol to Healthy Volunteers and Epileptic PatientsPharmacology, 1980